### Common Drug Review

**Product:** Invokana  
**Generic Name:** canagliflozin  
**Manufacturer:** Janssen Inc.  
**Indication:** Diabetes Mellitus, Type 2  
**Submission Status**

<table>
<thead>
<tr>
<th>Phase</th>
<th>Target Time (Business Days)</th>
<th>Target Date</th>
<th>Actual CDR Date</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Submission deemed complete</td>
<td>5</td>
<td>2013-Jun-12</td>
<td>- Submission voluntarily withdrawn by the manufacturer on 2013-Jun-07</td>
</tr>
</tbody>
</table>
| 2     | Patient group input submission received | 5           | 2013-Jun-26     | - Call for patient input posted on 2013-Jun-05  
- Patient group input deadline: 2013-Jun-26  
- Call for patient input closed as a result of a voluntary withdrawal of the submission by the manufacturer. |
| 3     | CADTH Reviewers’ Reports sent to Manufacturer | 45         |                |          |
| 4     | Comments from Manufacturer on Reviewers’ Reports  
Received by CADTH | 7           |                |          |
| 5     | CDEC Meeting                |             |                |          |
| 6     | CDEC Recommendation  
Sent to Drug Plans and Manufacturer | 5 to 7      |                |          |
| 7     | Embargo Period  
Manufacturers may make a Request for  
Reconsideration and Drug Plans may make a  
Request for Clarification of the Recommendation | 10          |                |          |
| 8 (a) | Final Recommendation sent to Drug Plans and  
Manufacturer  
(No Requests for Clarification are made AND no  
Request for Reconsideration is made or Request for  
Reconsideration is Resolved) | 5           |                |          |
| OR    |                             |             |                |          |
| 8 (b) | Clarification and Final Recommendation sent to Drug  
Plans and Manufacturer  
(Clarification Requested, no Request for  
Reconsideration made) | 5           |                |          |
| OR    |                             |             |                |          |
| 8 (c) | Placed on CDEC Agenda For Reconsideration  
(At Manufacturer’s request) | 25          | Depends on  
Meeting Dates  |          |
| 9     | Final Recommendation sent to Drug Plans and  
Manufacturer | 5           |                |          |

1 Refer to the Procedure for Common Drug Review on the Common Drug Review section of [www.cadth.ca](http://www.cadth.ca) for more details.
2 The target dates for this report are based on the CDEC meeting schedule, which is posted on www.cadth.ca.
3 The deadline for Patient Group Input is 15 business days after CADTH receives the Submission or up to 25 business days if advance notice of a Submission is received from the Manufacturer.
4 Target time is calculated, based on the date the Reviewers receive copies of the Manufacturer’s Submission. Target time does not include the time allocated for receipt of Manufacturer’s binders (5 business days) and time allocated for distribution of binders to reviewers (3 business days).
5 The Recommendation is held in confidence by all stakeholders and not acted upon until after CADTH has issued the notice of Final Recommendation. This Submission Status Report reflects status as of Thursday noon.